OncoMatch/Clinical Trials/NCT06910761
Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
Is NCT06910761 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for anatomic stage iv breast cancer ajcc v8.
This phase II trial tests how well craniospinal irradiation (CSI) using photon volumetric modulated arc radiotherapy (VMAT) works in treating patients with breast cancer or non-small cell lung cancer (NSCLC) that has spread from the original (primary) tumor to the cerebrospinal fluid and meninges (thin layers of tissue that cover and protect the brain and spinal cord) (leptomeningeal disease). Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. CSI (radiation therapy directed at the brain and spinal cord to kill tumor cells) may be able to target all of the areas of possible leptomeningeal tumor spread. Photon-VMAT-CSI may be an effective treatment option for patients with leptomeningeal disease secondary to breast cancer or NSCLC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Non-Small Cell Lung Carcinoma
Tumor Agnostic
Disease stage
Required: Stage LEPTOMENINGEAL DISEASE
Metastatic disease required
Leptomeningeal disease established either radiographically and/or CSF cytology
Prior therapy
Cannot have received: chemotherapy
Exception: within 7 days prior to day 1 of protocol therapy
Chemotherapy, biological therapy, immunotherapy within 7 days prior to day 1 of protocol therapy
Cannot have received: biological therapy
Exception: within 7 days prior to day 1 of protocol therapy
Chemotherapy, biological therapy, immunotherapy within 7 days prior to day 1 of protocol therapy
Cannot have received: immunotherapy
Exception: within 7 days prior to day 1 of protocol therapy
Chemotherapy, biological therapy, immunotherapy within 7 days prior to day 1 of protocol therapy
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥ 1,000/mm^3; hemoglobin ≥ 8 g/dl; platelet ≥ 100,000/mm^3
Kidney function
creatinine clearance of ≥ 50 ml/min per 24 hour urine test or the cockcroft-gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
- City of Hope at Irvine Lennar · Irvine, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify